First Report of Sorafenib in Patients With Acute Myeloid Leukemia Harboring Non-Canonical FLT3 Mutations

First Report of Sorafenib in Patients With Acute Myeloid Leukemia Harboring Non-Canonical FLT3 Mutations

The prognostics implications of patients with acute myeloid leukemia harboring non-canonical FLT3 is unknown. The use of tyrosine kinase inhibitors in this patient population has not been previously reported. We report successful targeted therapy against non-ITD, non-D835 driver FLT3 alterations in...

Full description

Bibliographic Details
Main Authors: Naval Daver, Allyson Price, Christopher B. Benton, Keyur Patel, Weiguo Zhang, Marina Konopleva, Naveen Pemmaraju, Koichi Takahashi, Michael Andreeff, Gautam Borthakur
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-08-01
Series:Frontiers in Oncology
Subjects:
sorafenib
FLT3 mutation
FLT3-V592
FLT3-N676
AML
TKI
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.01538/full
Description
Summary:The prognostics implications of patients with acute myeloid leukemia harboring non-canonical FLT3 is unknown. The use of tyrosine kinase inhibitors in this patient population has not been previously reported. We report successful targeted therapy against non-ITD, non-D835 driver FLT3 alterations in two patient case studies with acute myeloid leukemia.
ISSN:2234-943X

Similar Items